Research press release


Nature Medicine

A potential new treatment for osteoporosis



G Karsentyたちは、セロトニン生合成を阻害すると骨形成が増加して骨粗しょう症が治癒するかどうかを検証した。まず、セロトニン生合成のカギとなる酵素トリプトファンヒドロキシラーゼの阻害剤を開発し、これを骨粗しょう症のマウスとラットに1日1回、最長6週間投与したところ、この化合物は、骨形成を増加させることにより骨粗しょう症を防ぎ、改善させた。


Blocking the synthesis of serotonin could treat osteoporosis, according to a report published this week in Nature Medicine.

Osteoporosis is a disease of low bone mass often caused by excessive loss and poor formation of bones. Serotonin is best known for its role as a brain neurotransmitter, but this molecule is also produced by the gut and inhibits bone formation.

Gerard Karsenty and his colleagues tested whether blocking serotonin biosynthesis could treat osteoporosis by increasing bone formation. The researchers developed an inhibitor of tryptophan hydroxylase, a key enzyme in serotonin biosynthesis, and administered it once daily for up to six weeks to mice and rats with osteoporosis. They found that their compound both prevented and treated osteoporosis through an increase in bone formation.

The current treatment for osteoporosis, which acts by promoting bone formation, is the daily injection of parathyroid hormone. The results of this study highlight the potential of serotonin-synthesis blockers as a new generation of drugs to fight osteoporosis.

doi: 10.1038/nm.2098


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。